Production (Stage)
Travere Therapeutics, Inc.
TVTX
$15.84
$0.140.89%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -40.70% | -188.64% | -303.74% | 38.64% | 26.49% |
| Total Depreciation and Amortization | 11.22% | 13.04% | 15.83% | 72.49% | 98.62% |
| Total Amortization of Deferred Charges | 0.41% | 0.41% | 5.92% | 5.92% | 5.92% |
| Total Other Non-Cash Items | 152.66% | 155.51% | 156.35% | -417.33% | -525.54% |
| Change in Net Operating Assets | -1,040.93% | -147.38% | -71.79% | -92.33% | 65.66% |
| Cash from Operations | 49.46% | 15.19% | -3.04% | -18.10% | -49.89% |
| Capital Expenditure | -100.00% | -- | 183.36% | 183.11% | 195.45% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -81.88% | 78.08% | 341.78% | 358.02% | 275.49% |
| Cash from Investing | -81.93% | 78.08% | 351.59% | 386.51% | 292.41% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3,447.46% | -28.38% | -98.60% | -98.81% | -97.92% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 27.03% | -109.93% | -111.34% | -112.13% | -113.80% |
| Cash from Financing | 11,570.59% | -36.26% | -99.81% | -100.11% | -99.44% |
| Foreign Exchange rate Adjustments | -108.57% | -146.09% | -32.21% | -68.66% | 240.08% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 115.78% | 110.22% | -1,420.30% | 64.57% | -24.09% |